Organization
Day One Biopharmaceuticals
4 clinical trials
4 abstracts
Clinical trial
FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2022-12-22
Clinical trial
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway AberrationsStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Relapsed or Refractory Low-Grade GliomaStatus:
Abstract
Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.Org: Day One Biopharmaceuticals, The Preston Robert Tisch Brain Tumor Center,
Clinical trial
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic TherapyStatus: Recruiting, Estimated PCD: 2026-02-01
Abstract
Healthcare resource use for pediatric low-grade glioma care: A cohort of linked electronic health records and claims data.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Day One Biopharmaceuticals, Optum Lifesciences Inc.,
Abstract
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ), Children's National Hospital, Washington, DC, Seattle Children’s Hospital, Orlando Health Arnold Palmer Hospital for Children,
Abstract
Growing wiser with age: Results from the ACCELERATE Fostering Age Inclusive Research Group clinical trial survey.Org: Accelerate Platform (Innovation for Children and Adolescents with Cancer), Institut Bergonié, Gustave Roussy Département d'Organisation du Parcours Patient, EV Pharma Solutions Ltd., Novartis Pharmaceuticals Corporation,